title: Apoptic renal carcinoma cells are better inducers of cross-presenting activity than their primary necrotic counterpart.
abstract: Vaccination with tumor-loaded dendritic cells (DC) is a promising treatment strategy for patients with renal cell carcinoma (RCC). Cells undergoing cell death proved useful as a source of tumor antigen for DC loading. Both apoptotic and necrotic tumor cells have been shown to efficiently load RCC-tumor antigens on DC. However, no direct comparison of these two kinds of death has been attempted in the same RCC. We compared DC pulsed with apoptotic cells, whole cell lysates or their supernatants of the cell line K1, derived from a patient with clear cell RCC, to determine their ability to activate T cells. Monocyte-derived DCs were pulsed with the different sources of tumor antigen, matured and co-cultured with autologouos peripheral blood lymphocytes. After three weekly re-stimulations with DCs, generation of cytotoxic T lymphocytes CTL was assessed by IFN-gamma release in an ELISpot assay in the presence of the sensitizing target. By comparison with lysate, apoptotic tumor cells induced a higher frequency of MHC class I-restricted IFN-gamma releasing lymphocytes. A higher CTL response was induced by pulsing DCs with cell lysate supernatant compared with whole cell lysate. These results indicate that, although necrotic death has been regarded as highly permissive when compared to apoptotic death, the immunogenicity of the death treatment may vary from one tumor to another.
authors.affiliation: Faculteit Geneeskunde en Farmacie, Vrije Universiteit Brussel, Bruxel, Belgium.
authors.forename: E
authors.initials: E
authors.lastname: D' Hooghe
authors.forename: S
authors.initials: S
authors.lastname: Buttiglieri
authors.forename: G
authors.initials: G
authors.lastname: Bisignano
authors.forename: D
authors.initials: D
authors.lastname: Brusa
authors.forename: G
authors.initials: G
authors.lastname: Camussi
authors.forename: L
authors.initials: L
authors.lastname: Matera
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000938:Antigen-Presenting Cells / Q000502:physiology*; D000951:Antigens, Neoplasm / Q000494:pharmacology; D017209:Apoptosis / Q000502:physiology*; D002292:Carcinoma, Renal Cell / Q000276:immunology* / Q000473:pathology*; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000187:drug effects / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D018920:Coculture Techniques; D016207:Cytokines / Q000494:pharmacology; D003713:Dendritic Cells / Q000187:drug effects; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D007680:Kidney Neoplasms / Q000276:immunology* / Q000473:pathology*; D007959:Lymphocyte Culture Test, Mixed; D009336:Necrosis; D010641:Phenotype; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D016207:Cytokines; D007371:Interferon-gamma